PRESS RELEASE

First acquisition of a stake in a start-up by a French university hospital

The University Hospital of Montpellier (CHU de Montpellier), France, and its staff co-found the start-up MedXCell Science SAS and thus participate in the implementation of the medicine of tomorrow.

MedXCell Science SAS is dedicated to the development and marketing of innovative cell therapies which target osteoarticular disorders, such as osteoarthritis. This Montpellier-based start-up will eventually make affordable minimally-invasive advanced treatments with regenerative capacities. For the majority of these osteoarticular pathologies, the current therapies are only symptomatic and do not target the cause of the dysfunction.

MedXCell Science SAS exploits the clinical research of Prof. C. Jorgensen (Director of IRMB, Institute for Regenerative Medicine & Biotherapy in Montpellier), who has successfully tested the use of stem cells to treat osteoarthritis and degenerative disc disease (advanced low back pain), as well as the expertise and patent of Prof. J. De Vos and Dr D. Noël. As one of the founders of the start-up, the CHU de Montpellier becomes the first French university hospital acquiring a stake in a company that exploits academic discoveries.

MedXCell Science SAS will implement several technologies developed as part of the research activities of the CHU de Montpellier and its partners (including Inserm and the University of Montpellier). The new company will be housed in the Cyborg incubator, on the GDC-Saint Eloi campus, in close liaison with IRMB, and thus connected to the activities of healthcare and research. This strong synergy will stimulate sustainable job creation and economic activity in the Montpellier area.

The start-up is also co-founded by MedXCell SA, a Swiss company specialized in innovative therapies, whose goal is to become a global leader in regenerative medicine and sports medicine, notably thanks to its wide international network in professional sports. These innovative treatments will benefit both elite athletes and the numerous patients with osteoarticular disorders around the world, the latter representing a major societal burden.

August 28th, 2018